{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:08:01Z","timestamp":1789758481791,"version":"4.0.1"},"reference-count":51,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":692,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:p>In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side\u2010effects. To determine the incidence of these events, we performed a multicentre prospective study of the chelator. Blood counts were performed weekly, and confirmed neutropenia mandated discontinuation of therapy. Among 187 patients with thalassaemia major, the incidence of agranulocytosis (neutrophils &lt;\u20030.5\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/l) was 0.6\/100 patient\u2013years, and the incidence of milder forms of neutropenia (neutrophils 0.5\u20131.5\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/l) was 5.4\/100 patient\u2013years. All cases of neutropenia resolved after interruption of therapy. Neutropenia occurred predominantly in non\u2010splenectomized patients. Nausea and\/or vomiting occurred early in therapy, was usually transient and caused discontinuation of deferiprone in three patients. Mild to moderate joint pain and\/or swelling did not require permanent cessation of deferiprone and occurred more commonly in patients with higher ferritin levels. Mean alanine transaminase (ALT) levels rose during therapy. Increased ALT levels were generally transient and occurred more commonly in patients with hepatitis C. Persistent changes in immunological studies were infrequent, although sporadic abnormalities occurred commonly. Mean zinc levels decreased during therapy. Ferritin levels did not change in the overall group but decreased in those patients with baseline levels &gt;\u20032500\u2003\u03bcg\/l. This study characterized the safety profile of deferiprone, and, under the specific conditions of monitoring, demonstrated that agranulocytosis is less common than previously predicted.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2000.01866.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:21:45Z","timestamp":1047363705000},"page":"305-312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Safety profile of the oral iron chelator deferiprone: a multicentre study"],"prefix":"10.1111","volume":"108","author":[{"family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Galanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"DiPalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tricta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06445.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V80.3.593.593","article-title":"Efficacy and possible adverse effects of the oral iron chelator 1,2\u2010dimethyl\u20103\u2010hydroxypyrid\u20104\u2010one (L1) in thalassemia major","volume":"80","author":"Al\u2010Refaie F.N.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204494"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01323.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.7.657"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05274.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07888.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92483-I"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92443-W"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92585-2"},{"key":"e_1_2_6_12_2","unstructured":"Biesemeier J.A.&Laveglia J.(1991)14\u2010Day Oral Toxicity Study in Dogs with 1 2\u2010dimethyl\u20103\u2010hydroxy\u2010pyrid\u20104\u2010one (DMHP L1). National Institutes of Health Contract no. NO1\u2010DK\u20104\u20102255. Food and Drug Research Laboratories Waverly NY."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.156.3.1899759"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420116"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392313"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00144120"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2014.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30667-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb10478.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V92.2.632","article-title":"The iron chelator L1 potentiates oxidative DNA damage in iron\u2010loaded liver cells","volume":"92","author":"Cragg L.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01310.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80375-5"},{"key":"e_1_2_6_24_2","first-page":"564","article-title":"Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions","volume":"144","author":"Freedman M.H.","year":"1990","journal-title":"American Journal of Diseases of Childhood"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80131-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203853"},{"key":"e_1_2_6_27_2","first-page":"1","article-title":"Oral iron chelation","volume":"33","author":"Hoffbrand A.V.","year":"1996","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91721-5"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90641-7"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long\u2010term trial of deferiprone in 51 transfusion\u2010dependent iron overloaded patients","volume":"91","author":"Hoffbrand A.V.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90545-9"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90642-9"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07887.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390709"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90906-6"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196307112690201"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203854"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604033141402"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504063321404"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390701"},{"key":"e_1_2_6_43_2","first-page":"21b","article-title":"No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation","volume":"92","author":"Piga A.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(89)80027-7"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood.V78.10.2727.2727","article-title":"Comparison of the subacute toxicity and efficacy of 3\u2010hydroxypyrid\u20104\u2010one iron chelators in overloaded and non overloaded mice","volume":"78","author":"Porter J.B.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_46_2","unstructured":"Ramm G.A. Britton R.S. Brunt E.M. O'neill R. Bacon B.R.(1999) Hepatic iron overload in pathogen\u2010free gerbils does not result in bridging fibrosis or cirrhosis (abstract).Proceedings of the World Congress on Iron Metabolism (Bioiron '99) Sorrento Italy p.327."},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5319.1577"},{"key":"e_1_2_6_48_2","first-page":"1712","article-title":"Iron chelation therapy with oral deferiprone in patients with thalassemia (letter)","volume":"339","author":"Stella M.","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07915.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00725.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90264-X"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01866.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01866.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2000.01866.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T08:20:35Z","timestamp":1698567635000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2000.01866.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1046\/j.1365-2141.2000.01866.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01866.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}